[Endocannabinoid and endocannabinoid receptor antagonists].
Heinzl
Susanne
S
Redaktion Medizinische Monatsschrift für Pharmazeuten, Stuttgart. sheinzl@wissenschaftliche-verlagsgesellschaft.de
D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors* / Q000737:chemistry; D002986:Clinical Trials as Topic; D063388:Endocannabinoids; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000737:chemistry / Q000502:physiology; D000077285:Rimonabant; D014029:Tobacco Use Disorder / Q000188:drug therapy
D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D000077285:Rimonabant